Table. 3.

Impact of NACT among patients receiving curative and palliative intent treatment

Use of NACT Intent of treatment Overall survival (mon) Disease free survival (mon)


Median 95% CI p-value Median 95% CI p-value
Yes (84, 35.9%) Radical (25, 10.7%) 20.0 17.6–22.3 0.002 10.0 7.3–12.7 < 0.001
Palliative (59, 25.2%) 11.0 8.6–13.4 4.0 2.8–5.2
No (150, 64.1%) Radical (37, 15.8%) 16.0 9.8–22.3 9.0 6.9–11.1
Palliative (113, 48.3%) 13.0 11.2–14.8 6.0 3.9–8.0

The value in brackets includes the absolute number of patients followed by the percentage amongst total.

NACT, neoadjuvant chemotherapy; CI, confidence interval.

Ann Hepatobiliary Pancreat Surg 2023;27:180-8 https://doi.org/10.14701/ahbps.22-111
© 2023 Ann Hepatobiliary Pancreat Surg